News

Tsuji receives second largest NIH R01 grant in pharmacy school history to continue groundbreaking superbug research
1/9/20
BUFFALO, N.Y.—Brian Tsuji, professor of pharmacy practice and associate dean for clinical and translational sciences, is the principal investigator on a five-year $3.92 million R01 grant from the National Institutes of Health to continue his groundbreaking research to fight antibiotic-resistant bacteria.
Tsuji Lab highly successful at American Society for Microbiology annual conference
7/12/19
Professor Brian Tsuji and PhD candidate Nicholas Smith (PharmD '18 & MS '18) attended the 2019 American Society for Microbiology (ASM) Microbe annual conference in San Francisco.
Life-saving antibiotic receives new use guidelines from researchers around world
3/8/19
An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.
Ineffective antibiotics form strong teams against deadly super bacteria
5/23/17
A UB-led team of researchers found that combinations of three antibiotics – that are each ineffective against superbugs when used alone – are capable of eradicating two of the six ESKAPE pathogens when delivered together.
Once invincible superbug squashed by ‘superteam’ of antibiotics
8/21/17
University at Buffalo researchers have assembled a team of three antibiotics that, together, are capable of eradicating E. coli carrying mcr-1 and ndm-5 — genes that make the bacterium immune to last-resort antibiotics.

Unraveling how H. influenzae thrives in COPD patients
12/9/13
UB scores a perfect 10 on NIH grant application and is awarded multi-million dollar grant to study bacterium.